• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Lumexa Imaging Holdings Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation

    12/18/25 4:01:37 PM ET
    $LMRI
    Medical Specialities
    Health Care
    Get the next $LMRI alert in real time by email
    8-K
    false 0002071288 0002071288 2025-12-17 2025-12-17
     
     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    FORM 8-K

     

     

    CURRENT REPORT

    PURSUANT TO SECTION 13 OR 15(d)

    OF THE SECURITIES EXCHANGE ACT OF 1934

    Date of report (Date of earliest event reported): December 17, 2025

     

     

    Lumexa Imaging Holdings, Inc.

    (Exact Name of Registrant as Specified in its Charter)

     

     

     

    Delaware   001-43010   41-2605845
    (State or Other Jurisdiction
    of Incorporation)
     

    (Commission

    File Number)

      (IRS Employer
    Identification No.)

     

    4200 Six Forks Road  
    Suite 1000  
    Raleigh, North Carolina   27609
    (Address of Principal Executive Offices)   (Zip Code)

    (919) 763-1100

    (Registrant’s telephone number, including area code)

    Not applicable

    (Former Name or Former Address, if Changed Since Last Report)

     

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ☐

    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

    ☐

    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

    ☐

    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

    ☐

    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act:

    Securities registered pursuant to Section 12(b) of the Act

     

    Title of each class

     

    Trading
    Symbol

     

    Name of each exchange
    on which registered

    Common Stock, $0.001 par value per share   LMRI   The Nasdaq Stock Market LLC

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

    Emerging growth company ☒

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     
     


    Item 1.01. Entry into a Material Definitive Agreement.

    On December 17, 2025, Lumexa Imaging, Inc. and Lumexa Imaging Outpatient, Inc. (collectively, the “Borrowers”), each an indirect wholly-owned subsidiary of Lumexa Imaging Holdings, Inc. (the “Company”), the other Loan Parties party thereto, the Lenders party thereto and Barclays Bank PLC, as administrative agent, an Issuing Bank and the Swing Line Lender, entered into an amendment to their existing Credit Agreement (as so amended, the “Amended Credit Agreement”). Capitalized terms used herein and not otherwise defined have the meanings ascribed to them in the Amended Credit Agreement.

    The Amended Credit Agreement provides for (i) a secured term loan facility of $825 million (the “Refinancing Term Loan”) and (ii) a secured revolving line of credit of $250 million (the “Amended Revolving Credit Facility” and, together with the Refinancing Term Loan, the “Refinancing Senior Secured Credit Facility”). The Refinancing Term Loan will bear interest at a rate per annum equal to, at the option of the Borrowers, SOFR plus 3.00% or the Prime Rate plus 2.00%, and will mature in December 2032. The Amended Revolving Credit Facility will bear interest at a rate per annum equal to, at the option of the Borrowers, SOFR plus 3.00% or the Prime Rate plus 2.00% (subject to reduction upon the achievement of certain senior secured net leverage ratios), and will mature in December 2030.

    The Amended Credit Agreement contains various restrictive covenants that limit the ability of the Company’s subsidiaries to incur additional debt, pay dividends and other distributions, and engage in certain other transactions as specified therein. The Amended Credit Agreement also contains a financial covenant that must be met if outstanding revolving credit exposure exceeds 40% of the aggregate principal amount of the Amended Revolving Credit Facility on the last day of the applicable quarterly reporting period. If the covenant is triggered, the Company’s consolidated net leverage ratio on the last day of the test period shall not exceed 7.50 to 1. Failure to comply with these covenants could constitute an event of default notwithstanding the ability of the Company’s subsidiaries to meet their debt service obligations. The Amended Credit Agreement includes various customary remedies for the Lenders following an event of default. The Amended Credit Agreement is guaranteed by substantially all wholly-owned subsidiaries of the Company and is secured by substantially all of their assets, subject to certain exceptions.

    The foregoing description of the Amended Credit Agreement does not purport to be complete and is subject to, and qualified in its entirety by, the full text of the Amended Credit Agreement, which is attached hereto as Exhibit 10.1 and is incorporated herein by reference.

    Item 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.

    The information set forth under Item 1.01 of this Current Report on Form 8-K is incorporated by reference into this Item 2.03.

    Item 9.01. Financial Statements and Exhibits.

    (d) Exhibits.

     

    Exhibit No.    Description
    10.1    Amendment No. 5 to Credit Agreement, dated as of December 17, 2025, among Lumexa Imaging, Inc. and Lumexa Imaging Outpatient, Inc., as borrowers, Lumexa Imaging Intermediate Holdings, Inc. and Lumexa Imaging Outpatient Intermediate Holdings, Inc., as holding entities, the other Loan Parties party thereto, the Lenders party thereto and Barclays Bank PLC, as administrative agent, an Issuing Bank and the Swing Line Lender.
    104    Cover Page Interactive Data File (embedded within the Inline XBRL document)


    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

        LUMEXA IMAGING HOLDINGS, INC.
    Date: December 18, 2025     By:  

    /s/ Caitlin Zulla

        Name: Caitlin Zulla
        Title: Chief Executive Officer
    Get the next $LMRI alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $LMRI

    DatePrice TargetRatingAnalyst
    2/9/2026$23.00Outperform → Strong Buy
    Raymond James
    1/5/2026$23.00Overweight
    Analyst
    1/5/2026$23.00Buy
    Jefferies
    1/5/2026$22.00Overweight
    Wells Fargo
    1/5/2026Outperform
    William Blair
    1/5/2026$23.00Outperform
    Raymond James
    1/5/2026$23.00Outperform
    Leerink Partners
    1/5/2026$22.00Buy
    Deutsche Bank
    More analyst ratings

    $LMRI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Principal Accounting Officer Walker James Edward Jr. was granted 12,414 shares, increasing direct ownership by 252% to 17,346 units (SEC Form 4)

    4 - Lumexa Imaging Holdings, Inc. (0002071288) (Issuer)

    2/27/26 5:40:01 PM ET
    $LMRI
    Medical Specialities
    Health Care

    Chief Financial Officer Martin James Anthony was granted 54,054 shares (SEC Form 4)

    4 - Lumexa Imaging Holdings, Inc. (0002071288) (Issuer)

    1/15/26 12:51:17 PM ET
    $LMRI
    Medical Specialities
    Health Care

    SEC Form 3 filed by new insider Martin James Anthony

    3 - Lumexa Imaging Holdings, Inc. (0002071288) (Issuer)

    1/15/26 12:49:28 PM ET
    $LMRI
    Medical Specialities
    Health Care

    $LMRI
    SEC Filings

    View All

    Lumexa Imaging Holdings Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure

    8-K - Lumexa Imaging Holdings, Inc. (0002071288) (Filer)

    3/2/26 6:14:27 AM ET
    $LMRI
    Medical Specialities
    Health Care

    SEC Form SCHEDULE 13G filed by Lumexa Imaging Holdings Inc.

    SCHEDULE 13G - Lumexa Imaging Holdings, Inc. (0002071288) (Subject)

    2/13/26 2:36:25 PM ET
    $LMRI
    Medical Specialities
    Health Care

    SEC Form 8-K filed by Lumexa Imaging Holdings Inc.

    8-K - Lumexa Imaging Holdings, Inc. (0002071288) (Filer)

    1/15/26 6:48:58 AM ET
    $LMRI
    Medical Specialities
    Health Care

    $LMRI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Lumexa Imaging Holdings upgraded by Raymond James with a new price target

    Raymond James upgraded Lumexa Imaging Holdings from Outperform to Strong Buy and set a new price target of $23.00

    2/9/26 8:16:45 AM ET
    $LMRI
    Medical Specialities
    Health Care

    Analyst initiated coverage on Lumexa Imaging Holdings with a new price target

    Analyst initiated coverage of Lumexa Imaging Holdings with a rating of Overweight and set a new price target of $23.00

    1/5/26 9:16:52 AM ET
    $LMRI
    Medical Specialities
    Health Care

    Jefferies initiated coverage on Lumexa Imaging Holdings with a new price target

    Jefferies initiated coverage of Lumexa Imaging Holdings with a rating of Buy and set a new price target of $23.00

    1/5/26 8:58:21 AM ET
    $LMRI
    Medical Specialities
    Health Care

    $LMRI
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Middleby Appoints Glenn Eisenberg To Board of Directors

    The Middleby Corporation (NASDAQ:MIDD), a global leader in the foodservice industry, today announced the appointment of Glenn Eisenberg to its Board of Directors, effective March 1. With the addition of Mr. Eisenberg, the Middleby Board expands to twelve members. "We are pleased to welcome Glenn Eisenberg to the Middleby Board. His deep experience will be an immediate asset as we execute our strategic transformation," said Tim FitzGerald, Middleby CEO. "Glenn has a proven 20-year track record of success as a public company CFO and senior operating executive across complex global manufacturing businesses. His expertise in financial discipline, industrial manufacturing, capital allocation,

    3/6/26 7:00:00 AM ET
    $LH
    $LMRI
    $MIDD
    Medical Specialities
    Health Care
    Industrial Machinery/Components
    Industrials

    Lumexa Imaging Announces Participation in Upcoming Investor Conferences

    RALEIGH, N.C., Feb. 17, 2026 /PRNewswire/ -- Lumexa Imaging Holdings, Inc. ("Lumexa Imaging") (NASDAQ:LMRI), one of the nation's largest providers of outpatient imaging services, announced today that Caitlin Zulla, CEO, and Tony Martin, CFO, will participate in the following upcoming investor conferences: Raymond James Institutional Investors Conference, being held in Orlando, Florida, including a presentation at 3:25pm EST on Monday, March 2, 2026.Leerink Partners Global Healthcare Conference, being held in Miami, Florida, including a fireside chat at 8:40am EST on Monday, Marc

    2/17/26 7:30:00 AM ET
    $LMRI
    Medical Specialities
    Health Care

    Lumexa Imaging's Dr. Jennifer L. Kemp Elected to RSNA Board, Advancing National Leadership in Quality and Patient-Centered Care

    Chair of Lumexa Imaging's Center for Quality will serve as the Radiological Society of North America's board liaison for government relations RALEIGH, N.C., Jan. 28, 2026 /PRNewswire/ -- Lumexa Imaging (NASDAQ:LMRI), one of the nation's largest providers of outpatient imaging services, is proud to recognize Jennifer L. Kemp, MD, Chair of Lumexa Imaging's Center for Quality, has been elected to the Board of Directors of the Radiological Society of North America (RSNA). "Dr. Kemp's election to the RSNA Board reflects the depth of clinical leadership within our organization and t

    1/28/26 7:00:00 AM ET
    $LMRI
    Medical Specialities
    Health Care

    $LMRI
    Leadership Updates

    Live Leadership Updates

    View All

    Middleby Appoints Glenn Eisenberg To Board of Directors

    The Middleby Corporation (NASDAQ:MIDD), a global leader in the foodservice industry, today announced the appointment of Glenn Eisenberg to its Board of Directors, effective March 1. With the addition of Mr. Eisenberg, the Middleby Board expands to twelve members. "We are pleased to welcome Glenn Eisenberg to the Middleby Board. His deep experience will be an immediate asset as we execute our strategic transformation," said Tim FitzGerald, Middleby CEO. "Glenn has a proven 20-year track record of success as a public company CFO and senior operating executive across complex global manufacturing businesses. His expertise in financial discipline, industrial manufacturing, capital allocation,

    3/6/26 7:00:00 AM ET
    $LH
    $LMRI
    $MIDD
    Medical Specialities
    Health Care
    Industrial Machinery/Components
    Industrials